Evidence map›Paper›PMID 24717328›Full record

ArticleBehavioural brain research2014

Antidepressant effects of resveratrol in an animal model of depression.

Laura L Hurley, Luli Akinfiresoye, Olubukola Kalejaiye, Yousef Tizabi

Abstract read
In one paragraph

Article in Behavioural brain research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Characterization of antidepressant activity ofAmerican journal of translational research · 2022
    Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Laura L HurleyDepartment of Pharmacology, Howard University College of Medicine, Washington, DC 20059, USA.
Luli AkinfiresoyeDepartment of Pharmacology, Howard University College of Medicine, Washington, DC 20059, USA.
Olubukola KalejaiyeDepartment of Pharmacology, Howard University College of Medicine, Washington, DC 20059, USA.
Yousef TizabiDepartment of Pharmacology, Howard University College of Medicine, Washington, DC 20059, USA. Electronic address: ytizabi@howard.edu.
Howard University · US

Funding

The Howard University SCORE Program Supplemental GrantS06GM008016 · NIGMS · HOWARD UNIVERSITY · PI WALCOURT, ASIKIYA · 1989 to 2009
$16.1M
PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
NIGMS NIH HHS 2 SO6 GM08016-39NIGMS NIH HHS S06 GM008016NIMHD NIH HHS G12 MD007597
6 · The paper itself

Abstract

Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a natural non-flavonoid polyphenol antioxidant extracted from red grapes in the processing of wine. Initially it was studied for its potential as anticancer drug, and later was found to reduce cardiovascular disease. More recently resveratrol was shown to alleviate depressive-like symptoms induced by stress or other means in mice and rats. The major purpose of this study was to investigate whether resveratrol would manifest an antidepressant effect in Wistar-Kyoto (WKY) rats, a putative and non-induced animal model of depression, and whether this effect might be associated with an increase in hippocampal and frontal cortical brain-derived neurotrophic factor (BDNF), a protein implicated in chronic effects of many antidepressants. Adult male WKY rats were injected with two doses of resveratrol (10 and 40 mg/kg, i.p.) and their behavior in the open field locomotor activity (LMA), forced swim test (FST: a measure of helplessness), and sucrose preference test (SPT: a measure of anhedonia) was evaluated after a single acute injection or following 7 days of daily treatment. Both acute and chronic administration of resveratrol resulted in a dose-dependent decrease in FST. However, only chronic resveratrol resulted in dose-dependent increase in sucrose consumption. LMA was not affected by any treatment. Parallel to the observed behavioral effects the level of hippocampal, but not frontal cortical, BDNF was also dose-dependently elevated after chronic resveratrol administration. These findings indicate an antidepressant-like effect of resveratrol in an animal model of depression possibly via activation of hippocampal BDNF, and suggest therapeutic potential of resveratrol in at least a subpopulation of depressed patients.

Indexed as

AnhedoniaAnimalsAntidepressive AgentsBlotting, WesternBrain-Derived Neurotrophic FactorDepressive DisorderDisease Models, AnimalDose-Response Relationship, DrugFrontal LobeHippocampusMaleMotor ActivityNeuropsychological TestsRats, Inbred WKYResveratrolStilbenesAntidepressive AgentsBrain-Derived Neurotrophic FactorResveratrolStilbenesAnimal modelBDNFDepressionHippocampusResveratrol

Identifiers

PMID24717328
PMCPMC4033784
OpenAlexW2073481546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.